Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07448298) titled 'A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases' on Feb. 26.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Beijing Boren Hospital

Condition: Relapsed/Refractory Autoimmune Diseases

Intervention: Biological: AFN50 injection

Recruitment Status: Recruiting

Phase: Early Phase 1

Date of First Enrollment: March 9, 2026

Target Sample Size: 18

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07448298

Published by HT Digital...